HSR waiting period expires for Lilly's acquisition of Centessa; condition satisfied

Centessa Pharmaceuticals plc

Hart-Scott-Rodino waiting period expired at 11:59 p.m. on May 21, 2026, clearing antitrust review.
Acquisition of Centessa by Eli Lilly announced March 31, 2026; remains subject to shareholder vote and court sanction.
Proxy statement filed May 7, 2026; shareholders urged to vote on the scheme of arrangement.
Closing requires approval by Centessa shareholders and sanction by High Court of Justice of England and Wales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.